Current Opinion in Pharmacology

Current Opinion in Pharmacology is published by Elsevier BV and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diverse Scientific and Economic Studies, Receptor Mechanisms and Signaling and Human auditory perception and evaluation, together about 24.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)

Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis of current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight into areas of importance.COPHAR is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Pharmacology and Drug Discovery (CRPHAR).COPHAR publishes the latest advancements in pharmacological sciences, covering, but not limited to, the following human systems:Cardiovascular systemsDigestive and excretory systemsEndocrine systemImmune and lymphatic systemsMusculoskeletal systemNervous systemReproductive systemRespiratory systemUrinary and renal systemsAdditionally, COPHAR particularly welcomes submissions related to:CancerImmunomodulationAnti-infectivesMetabolic disordersNeurological and psychiatric disordersEmerging technologiesGender and agingThe journal builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.Expertise - Expert authors, who are leaders in their field, are invited to write short review articles in which they present recent developments in their subject and provide short annotations to the papers that they think are most relevant.Comprehensiveness - There are 27 high-impact Current Opinion review journals in a range of subjects from food science to green and sustainable chemistry.Impact - In addition to a vast readership, Current Opinion titles enjoy high citations, Impact Factors, and CiteScores.Discoverability: Articles get high visibility and maximum exposure on an industry-leading platform that reaches a vast, global audience.Selection of topics to be reviewed Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.SubmissionsCurrent Opinion in Pharmacology allows two ways to submit to the journal:Invitation – in accordance with the established procedure for all Current Opinion titles, andNEW– authors are given a “spontaneous submission option” via the submission portal “General Pharmacology” at https://www.editorialmanager.com/cophar/default2.aspx to open the journal to the authorship fully.Short Reviews Authors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.Editorial Overview Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in th

From the journal's Aims & Scope

Research area (LetPub): Pharmacology & Pharmacy

Editor-in-chief Shengtao HouPublisher website

Editorial board by country: 6 in mainland China (about 18%); most named United Kingdom 8, Mainland China 6, France 5, Italy 4, United States 2 (33 members with a country) Editorial board ↗Publisher website · 2026-10-01

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

5.48LetPub · 2026-09-13

Impact factor (publisher)

5.5Publisher website · 2026-10-01

CiteScore 2026-06

12.2LetPub · 2026-09-13

CiteScore (publisher)

12.2Publisher website · 2026-10-01

SJR 2026-06

1.52LetPub · 2026-09-13

SNIP 2026-06

1.33LetPub · 2026-09-13

h-index

120LetPub · 2026-09-13

h-index

176OpenAlex · 2026-10-01

i10-index

2,111OpenAlex · 2026-10-01

2-year mean citedness

4.06OpenAlex · 2026-10-01

Self-citation rate

5.5%LetPub · 2026-09-13

Share of gold OA articles

33.66%LetPub · 2026-09-13

Volume

Articles per year

39LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

4–8 weeksLetPub · 2026-09-13

Average acceptance (community reports)

ModerateLetPub · 2026-09-13

Submission to first decision

18 daysPublisher website · 2026-10-01

First decision after review

55 daysPublisher website · 2026-10-01

Submission to acceptance

98 daysPublisher website · 2026-10-01

Acceptance to publication

7 daysPublisher website · 2026-10-01

Peer review

Single anonymous peer reviewPublisher website

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Elsevier BV

Country or region

ENGLAND

Language

English

Frequency

Bimonthly

Founded

2001

ISSN

1471-4892

Electronic ISSN

1471-4973

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗Publisher website
• Special issues ↗Publisher website